Join this live webinar to learn more.
Rapid advances in oncology such as cell therapies, antibody-drug conjugates, biomarker-driven treatments, and increasingly adaptive trial designs (including basket, umbrella, and platform studies) are transforming how cancer drugs are developed. While these breakthroughs hold enormous promise, they also introduce new operational challenges related to patient identification, evolving protocols, specialized sites, complex logistics, and trial execution across multiple cohorts and arms.
As innovation accelerates, clinical operations teams must ensure study designs remain feasible for sites and accessible for patients, while managing the added complexity of adaptive frameworks that require ongoing coordination of data, sites, and regulatory oversight. In this session, leaders discuss strategies for translating cutting-edge oncology science and novel trial designs into operationally executable trials.
Key Discussion Points
- Operational implications of emerging oncology modalities, precision medicine approaches, and adaptive trial designs
- Managing biomarker screening, specialized sites, evolving protocols, and complex trial logistics
- Coordinating sites, data flow, and oversight across multi-arm and platform studies
- Aligning protocol design with site capacity and patient access
- Balancing scientific innovation and trial flexibility with operational feasibility in oncology trials
Offered Free by: Advarra
See All Resources from: Advarra
